Wed, Jan 28, 2015, 7:34 AM EST - U.S. Markets open in 1 hr 56 mins

Recent

% | $
Quotes you view appear here for quick access.

Dendreon Corporation Message Board

  • busy26795 busy26795 Sep 27, 2013 7:47 AM Flag

    DNDN " setting suggest long-lived immunological memory to PROVENGE years following initial treatment."

    DNDN

    Dendreon announces presentation of PROVENGE (sipuleucel-T) data at the 2013 European Cancer Congress; Phase II study demonstrates robust immune response when PROVENGE is administered with abiraterone acetate

    Co announced the presentation of data from clinical studies featuring PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for metastatic castrate-resistant prostate cancer (mCRPC), at the 2013 European Cancer Congress in Amsterdam, September 27-October 1, 2013. Preliminary Phase II data surrounding DN24-02, an investigational autologous cellular immunotherapy for patients with surgically resected HER2+ urothelial cancer, will also be presented. Preliminary data from a Phase II combination study demonstrated that PROVENGE product potency and immunological prime-boost responses are maintained when administered concurrently or sequentially with abiraterone acetate (AA) plus prednisone. Additionally, preliminary data from an ongoing open-label study of PROVENGE treatment in men with mCRPC who were previously treated with PROVENGE in the androgen dependent prostate cancer (ADPC) setting suggest long-lived immunological memory to PROVENGE years following initial treatment.

    Sentiment: Strong Buy

 
DNDN
0.1270.000(0.00%)Nov 18 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Apple Inc.
NASDAQTue, Jan 27, 2015 4:00 PM EST
Anthem, Inc.
NYSETue, Jan 27, 2015 4:01 PM EST
ABIOMED, Inc.
NASDAQTue, Jan 27, 2015 4:00 PM EST